Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: Perspective from a developing country

Research in Developmental Disabilities

Volumn 33, Issue 2, 2012, Pages 563-569

  Memari, Amir Hossein ^a   Ziaee, Vahid ^a   Beygi, Sara ^a   Moshayedi, Pouria ^b   Mirfazeli, Fatemeh Sadat ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Autism spectrum disorder; Children; Developing country; Prevalence; Psychotropic medication

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; HYPNOTIC SEDATIVE AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADOLESCENT; AGE; ARTICLE; AUTISM; CHILD; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG USE; EDUCATION; FEMALE; HUMAN; INCOME; INTERVIEW; IRAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL HISTORY; POVERTY; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DEVELOPING COUNTRIES; DRUG COSTS; DRUG LABELING; FEMALE; HUMANS; IRAN; MALE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PSYCHOTROPIC DRUGS;

EID: 82055172855     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2011.10.001     Document Type: Article

References (42)

1. Al Anbar N.N., Dardennes R.M., Prado-Netto A., Kaye K., Contejean Y. Treatment choices in autism spectrum disorder: The role of parental illness perceptions. Research in Developmental Disabilities 2010, 31(3):817-828.
2. Aman M.G., Arnold L.E., Armstrong S.C. Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 1999, 5(4):279-289.
3. Aman M.G., Lam K.S.L., Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders 2003, 33(5):527-534.
4. Aman M.G., Lam K.S.L., Van Bourgondien M.E. Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child & Adolescent Psychopharmacology 2005, 15(1):116-126.
5. Aman M.G., Van Bourgondien M.E., Wolford P.L., Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child & Adolescent Psychiatry 1995, 34(12):1672-1681.
6. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Author, Washington, DC. 4th ed. - text revision.
7. Barnard L., Young A., Pearson J., Geddes J., O'Brien G. A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology 2002, 16(1):93.
8. Bowker A., D'Angelo N.M., Hicks R., Wells K. Treatments for autism: Parental choices and perceptions of change. Journal of Autism and Developmental Disorders 2011, 41(10):1373-1382.
9. Calles J.L. Use of psychotropic medications in children with developmental disabilities. Pediatric Clinics of North America 2008, 55(5):1227-1240.
10. Copeland L.A., Zeber J.E., Valenstein M., Blow F.C. Racial disparity in the use of atypical antipsychotic medications among veterans. American Journal of Psychiatry 2003, 160(10):1817.
11. Dardennes R.M., Al Anbar N.N., Prado-Netto A., Kaye K., Contejean Y. Treating the cause of illness rather than the symptoms: Parental causal beliefs and treatment choices in autism spectrum disorder. Research in Developmental Disabilities 2011, 32(3):1137-1146.
12. Esbensen A.J., Greenberg J.S., Seltzer M.M., Aman M.G. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders 2009, 39(9):1339-1349.
13. Green V.A., Pituch K.A., Itchon J., Choi A., O'Reilly M., Sigafoos J. Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities 2006, 27(1):70-84.
14. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2004, 30(3):582-589.
15. Jesner O.S., Aref-Adib M., Coren E. Risperidone for autism spectrum disorder. Cochrane Database Systematic Reviews 2007, (1):CD005040.
16. King B.H., Hollander E., Sikich L., McCracken J.T., Scahill L., Bregman J.D., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry 2009, 66(6):583-590.
17. Kolevzon A., Mathewson K.A., Hollander E. Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. Journal of Clinical Psychiatry 2006, 67(3):407-414.
18. Kuno E., Rothbard A.B. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 2002, 159(4):567.
19. Lakhan S.E., Hagger-Johnson G.E. The impact of prescribed psychotropics on youth. Clinical Practice and Epidemiology in Mental Health 2007, 3(1):21.
20. Langworthy-Lam K.S., Aman M.G., Van Bourgondien M.E. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 2002, 12(4):311-321.
21. Lord C., Rutter M., Le Couteur A. Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 1994, 24:659-685.
22. Malone R.P., Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. Drugs 2009, 69(5):535-548.
23. Mandell D.S., Morales K.H., Marcus S.C., Stahmer A.C., Doshi J., Polsky D.E. Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008, 121(3):e441.
24. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2009, 48(11):1110-1119.
25. Martin A., Scahill L., Klin A., Volkmar F.R. Higher-functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child & Adolescent Psychiatry 1999, 38(7):923-931.
26. Matson J.L., Hess J.A. Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Research in Autism Spectrum Disorders 2011, 5(1):230-236.
27. Matson J.L., Worley J.A., Fodstad J.C., Chung K.M., Suh D., Jhin H.K., et al. A multinational study examining the cross cultural differences in reported symptoms of autism spectrum disorders: Israel, South Korea, the United Kingdom, and the United States of America. Research in Autism Spectrum Disorders 2011, 5(4):1598-1604.
28. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002, 347(5):314-321.
29. Melfi C.A., Croghan T.W., Hanna M.P., Robinson R.L. Racial variation in antidepressant treatment in a Medicaid population. Journal of Clinical Psychiatry 2000, 61(1):16-21.
30. Memari A.H., Kordi R., Ziaee V., Mirfazeli F.S., Setoodeh M.S. Weight status in Iranian children with autism spectrum disorders: Investigation of underweight, overweight and obesity. Research in Autism Spectrum Disorders 2012, 6(1):234-239.
31. Myers S.M., Johnson C.P. Management of children with autism spectrum disorders. AAP Policy 2007, 120(5):1162.
32. Oswald D.P., Sonenklar N.A. Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology 2007, 17(3):348-355.
33. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124(6):1533.
34. Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders 2007, 37(2):367-373.
35. Pi E.H., Simpson G.M. Psychopharmacology: Cross-cultural psychopharmacology: A current clinical perspective. Psychiatric Services 2005, 56(1):31.
36. Posey D.J., Stigler K.A., Erickson C.A., McDougle C.J. Antipsychotics in the treatment of autism. Journal of Clinical Investigation 2008, 118(1):6-14.
37. Rimland, B.,and Edelson, M. (1999). The autism treatment evaluation checklist (ATEC). In (Vol. January 2011).
38. Rosenberg R.E., Mandell D.S., Farmer J.E., Law J.K., Marvin A.R., Law P.A. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders 2010, 40(3):342-351.
39. Scahill L., Koenig K., Carroll D., Pachler M. Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child and Adolescent Psychiatric Nursing: Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc 2007, 20(3):188.
40. Stigler K.A., McDougle C.J. Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America 2008, 17(4):739-752.
41. Tsakanikos E., Costello H., Holt G., Sturmey P., Bouras N. Behaviour management problems as predictors of psychotropic medication and use of psychiatric services in adults with autism. Journal of Autism and Developmental Disorders 2007, 37(6):1080-1085.
42. Witwer A., Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child & Adolescent Psychopharmacology 2005, 15(4):671-681.